Head to Head Survey: Nexalin Technology (NASDAQ:NXL) and SiBone (NASDAQ:SIBN)

SiBone (NASDAQ:SIBN) and Nexalin Technology (NASDAQ:NXL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for SiBone and Nexalin Technology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1	0	6	0	2.71
Nexalin Technology	1	1	0	0	1.50

SiBone currently has a consensus price target of $24.17, indicating a potential upside of 26.28%. Given SiBone’s stronger consensus rating and higher possible upside, equities research analysts clearly believe SiBone is more favorable than Nexalin Technology.

Insider & Institutional Ownership

98.1% of SiBone shares are owned by institutional investors. Comparatively, 0.6% of Nexalin Technology shares are owned by institutional investors. 4.0% of SiBone shares are owned by insiders. Comparatively, 16.9% of Nexalin Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk & Volatility

SiBone has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.08, meaning that its stock price is 308% more volatile than the S&P 500.

Valuation & Earnings

This table compares SiBone and Nexalin Technology”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93 million	4.22	-$18.90 million	($0.34)	-56.29
Nexalin Technology	$217,155.00	15.87	-$8.22 million	($14.41)	-0.33

Nexalin Technology has lower revenue, but higher earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares SiBone and Nexalin Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SiBone	-6.85%	-8.23%	-6.07%
Nexalin Technology	-4,141.94%	-278.24%	-218.42%

Summary

SiBone beats Nexalin Technology on 9 of the 14 factors compared between the two stocks.

About SiBone

SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.